Provided by Tiger Trade Technology Pte. Ltd.

Compass Therapeutics, Inc.

6.69
+0.17002.61%
Volume:1.37M
Turnover:9.14M
Market Cap:1.19B
PE:-14.83
High:6.82
Open:6.50
Low:6.40
Close:6.52
52wk High:6.88
52wk Low:1.33
Shares:177.86M
Float Shares:123.05M
Volume Ratio:0.59
T/O Rate:1.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4512
EPS(LYR):-0.3594
ROE:-37.82%
ROA:-23.47%
PB:5.68
PE(LYR):-18.61

Loading ...

Company Profile

Company Name:
Compass Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
35
Office Location:
80 Guest Street,Suite 601,Boston,Massachusetts,United States
Zip Code:
02135
Fax:
- -
Introduction:
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.